Recruitment and eligibility in a Phase 1 early Alzheimer&#39;s disease trial of Sabirnetug.

sabirnetug IV (ACU193 IV) - Acumen Pharma

http://www.ncbi.nlm.nih.gov/pubmed/41070367

Alyssa Carroll; Eric Siemers; Gopalan Sethuraman; Janice Hitchcock; Karen Sundell; Robyn Moxon; Siew Tin Gan; Todd Feaster; Vladimir Skljarevski

Oct 10, 2025